Amgen Inc.

Vigil Neuroscience, Inc.

Teijin Pharma Limited

Jane Panteleev

Ryan D White

Jonathan B Houze

Gwenaella Rescourio

Haoxuan Wang

Vincent Santora

Yongwei Wu

Timothy Hopper

Lara C Czabaniuk

Alice R Wong

Maxence Bos

John Mancuso

Ivan Franzoni

Matthew M Weiss

Angel Guzman-Perez

Laurie B Schenkel

Michael D Bartberger

Daniel B Horne

Zihao Hua

John Stellwagen

Nagasree Chakka

Benjamin Charles Milgram

Daniel C H Lin

Hua Gao

Wei Zhao

Madeleine Kieffer

Angel Guzman-perez

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2').  This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

Benzimidazole derivatives and their uses

Growing community of inventors

Charlestown, MA, United States of America

Jane Panteleev